[{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CVL-936","moa":"D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Cyclica","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ Cerevel Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cerevel Therapeutics \/ Cerevel Therapeutics"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"PIPE","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"CVL-231","moa":"Muscarinic M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ PIPE","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Therapeutics \/ PIPE"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CVL-865","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darigabat","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"NovaQuest","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ NovaQuest","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ NovaQuest"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CVL-231","moa":"Muscarinic M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CVL-871","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CVL-871","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CVL-231","moa":"Muscarinic M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"Muscarinic M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"Muscarinic M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley & Co","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley & Co"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emraclidine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emraclidine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Herophilus","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ Cerevel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cerevel Therapeutics \/ Cerevel Therapeutics"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Emraclidine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":8.6999999999999993,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":8.6999999999999993,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tavapadon","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tavapadon","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cerevel Therapeutics","amount2":8.6999999999999993,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Cerevel Therapeutics \/ Abbvie Inc"}]
Find Clinical Drug Pipeline Developments & Deals by Cerevel Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
